Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk.